DK3177646T3 - Cd3-bindingsdomæne - Google Patents
Cd3-bindingsdomæne Download PDFInfo
- Publication number
- DK3177646T3 DK3177646T3 DK15756850.2T DK15756850T DK3177646T3 DK 3177646 T3 DK3177646 T3 DK 3177646T3 DK 15756850 T DK15756850 T DK 15756850T DK 3177646 T3 DK3177646 T3 DK 3177646T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding domain
- domain
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Gyroscopes (AREA)
- Optical Communication System (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3177646T3 true DK3177646T3 (da) | 2020-12-07 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15756850.2T DK3177646T3 (da) | 2014-08-07 | 2015-08-05 | Cd3-bindingsdomæne |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (da) |
| EP (2) | EP2982693A1 (da) |
| JP (1) | JP6669722B2 (da) |
| CN (1) | CN107001468B (da) |
| AU (1) | AU2015299039B2 (da) |
| BR (1) | BR112017002422B1 (da) |
| CA (1) | CA2957462C (da) |
| DK (1) | DK3177646T3 (da) |
| HR (1) | HRP20202024T1 (da) |
| HU (1) | HUE051919T2 (da) |
| LT (1) | LT3177646T (da) |
| RU (1) | RU2742691C2 (da) |
| SI (1) | SI3177646T1 (da) |
| WO (1) | WO2016020444A1 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2929256C (en) | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL307276B1 (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| BR112018003984A2 (pt) | 2015-12-09 | 2018-09-25 | Hoffmann La Roche | anticorpos |
| JP7030704B2 (ja) | 2016-02-05 | 2022-03-08 | オリオニス バイオサイエンシズ ビーブイ | 二重特異性シグナル伝達物質およびその使用 |
| BR112019022558A2 (pt) | 2016-06-02 | 2020-05-19 | Hoffmann La Roche | anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| TW201834688A (zh) | 2017-02-24 | 2018-10-01 | 日商中外製藥股份有限公司 | 藥學組成物、抗原結合分子、治療方法以及篩選方法 |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| CN110770255A (zh) | 2017-04-11 | 2020-02-07 | 印希彼有限公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| JP7247110B2 (ja) * | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｃｄ３抗体 |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| EP3668898B1 (en) | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| KR101973060B1 (ko) | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| EP3753956A4 (en) * | 2018-02-14 | 2021-12-22 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN BINDING MOLECULE AND COMBINATION |
| AU2019235523A1 (en) | 2018-03-14 | 2020-10-29 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
| MA52773A (fr) * | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-cd3 et leurs utilisations |
| JP7651450B2 (ja) * | 2018-07-24 | 2025-03-26 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法 |
| CA3109513A1 (en) * | 2018-08-23 | 2020-02-27 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| EA202192654A1 (ru) * | 2019-03-29 | 2021-12-30 | Грин Кросс Корпорейшн | Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения |
| TW202140561A (zh) * | 2020-02-14 | 2021-11-01 | 日商協和麒麟股份有限公司 | 與cd3結合之雙特異性抗體 |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| KR20240005722A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체를 사용한 치료를 위한 투약 |
| JP2024523033A (ja) | 2021-06-17 | 2024-06-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の三重特異的結合分子 |
| EP4458851A1 (en) | 2021-12-31 | 2024-11-06 | Kyinno Biotechnology Co., Ltd. | Anti-gprc5d antibody and use thereof |
| WO2023125729A1 (zh) * | 2021-12-31 | 2023-07-06 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| EP4496631A1 (en) | 2022-03-23 | 2025-01-29 | F. Hoffmann-La Roche AG | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| EP4508081A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| CN100500846C (zh) * | 1999-03-09 | 2009-06-17 | 津莫吉尼蒂克斯公司 | 作为zalpha受体之配体的人细胞因子及其用途 |
| EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| JP4762158B2 (ja) | 2004-02-16 | 2011-08-31 | ミクロメット・アクチェンゲゼルシャフト | 低い免疫原性を有する結合分子 |
| EP2385065A1 (en) * | 2007-11-01 | 2011-11-09 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| AU2012233313C1 (en) * | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| HUE044209T2 (hu) * | 2011-05-21 | 2019-10-28 | Macrogenics Inc | Humán és nem humán CD3-hoz kötõdni képes CD3-kötõ molekulák |
| US9915665B2 (en) * | 2012-12-28 | 2018-03-13 | Abbvie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CA2920173C (en) * | 2013-08-07 | 2021-08-10 | Affimed Therapeutics Ag | Antibody binding sites specific for egfrviii |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en active Application Filing
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
-
2020
- 2020-12-17 HR HRP20202024TT patent/HRP20202024T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2957462A1 (en) | 2016-02-11 |
| HUE051919T2 (hu) | 2021-04-28 |
| US20160039934A1 (en) | 2016-02-11 |
| WO2016020444A1 (en) | 2016-02-11 |
| JP6669722B2 (ja) | 2020-03-18 |
| US10066015B2 (en) | 2018-09-04 |
| CN107001468B (zh) | 2021-04-09 |
| LT3177646T (lt) | 2021-01-11 |
| AU2015299039A1 (en) | 2017-03-02 |
| CA2957462C (en) | 2023-10-17 |
| BR112017002422B1 (pt) | 2024-02-20 |
| HRP20202024T1 (hr) | 2021-02-19 |
| EP2982693A1 (en) | 2016-02-10 |
| BR112017002422A2 (pt) | 2017-11-28 |
| EP3177646B1 (en) | 2020-10-07 |
| EP3177646A1 (en) | 2017-06-14 |
| AU2015299039B2 (en) | 2021-01-21 |
| JP2017529067A (ja) | 2017-10-05 |
| RU2017105120A (ru) | 2018-09-10 |
| RU2017105120A3 (da) | 2019-02-20 |
| SI3177646T1 (sl) | 2021-04-30 |
| RU2742691C2 (ru) | 2021-02-09 |
| CN107001468A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3177646T3 (da) | Cd3-bindingsdomæne | |
| DK3411065T3 (da) | Clec9a-bindingsmidler | |
| DK3143042T3 (da) | Forbedrede variable immunoglobulindomæner | |
| DK3466976T3 (da) | Anti-her2-antistof-lægemiddelkonjugat | |
| IL247299B (en) | Complement component c5 antibodies | |
| DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
| DK3006072T3 (da) | Karadgang | |
| MA55696A (fr) | Combinaisons | |
| LT3166970T (lt) | Patobulinti a-beta protofibriles surišantys antikūnai | |
| DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
| DE112015001664A5 (de) | Betätigungsaktuator | |
| EP3497189C0 (en) | BRIQUETTES | |
| DK3110439T3 (da) | Pcsk9-vacciner | |
| HUE054148T2 (hu) | Anti-ORAI1 antitest | |
| LT3628731T (lt) | Naujas antipresepsino antikūnas | |
| DE112015005041A5 (de) | Gargerätevorrichtung | |
| LT3126391T (lt) | Hpa-1a antikūnai | |
| IL251479B (en) | Compositions | |
| DE102014000623A8 (de) | Halbhohlnietelement | |
| DK3009858T3 (da) | Skyradar | |
| DE112015001633A5 (de) | Betätigungsaktuator | |
| DK3334807T3 (da) | Ildtænder | |
| DE112015004799A5 (de) | Schwungrad | |
| DK3091875T3 (da) | Vipbar taburet | |
| DE202014005655U8 (de) | llluminationsvorrichtung |